Rifampicin

Generic Name: Rifampicin

Brand Names: Isonarif, Rifadin, Rifamate, Rifater, Rofact

Drug Type: Small Molecule

Chemical Formula: C_₄₃H_₅₈N_₄O_₁₂

CAS Number: 13292-46-1

Unique Ingredient Identifier: VJT6J7R4TR

Background: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)

Indication: Rifampin is indicated for the treatment of tuberculosis and tuberculosis-related mycobacterial infections. In combination with pyrazinamide and isoniazid, it is used in the initial phase of the short-course treatment of pulmonary tuberculosis.

Associated Conditions: Cholestatic pruritus, MRSA Infections, Prosthetic Joint Infections, Asymptomatic Neisseria meningitidis carrier of the nasopharynx, Initial phase Tuberculosis, Late phase Tuberculosis

Associated Therapies: Antibacterial therapy

Clinical Trials

Study to Assess the Effect of Rifampicin (CYP Inducer) on Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours

Phase 1

Completed

Conditions: Solid Tumours

Interventions: Procedure: Pharmacokinetic sampling
Drug: Rifampicin
Drug: Olaparib tablet dosing

First Posted Date: 2013-08-28

Last Posted Date: 2017-01-16

Lead Sponsor: AstraZeneca

Target Recruit Count: 32

Registration Number: NCT01929603

Locations: 🇳🇱
Research Site, Maastricht, Netherlands

A Study of Baricitinib and Rifampicin in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Baricitinib
Drug: Rifampicin

First Posted Date: 2013-07-29

Last Posted Date: 2017-06-06

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 18

Registration Number: NCT01910311

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leeds, West Yorkshire, United Kingdom

A Study of Evacetrapib and Rifampin in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Evacetrapib
Drug: Rifampin

First Posted Date: 2013-07-25

Last Posted Date: 2018-10-03

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 26

Registration Number: NCT01908582

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madison, Wisconsin, United States

Effects of Rifampicin on the Pharmacokinetics and Pharmacodynamics of Sublingual and Intravenous Buprenorphine

Phase 4

Completed

Conditions: Healthy

Interventions: Drug: Buprenorphine
Drug: Placebo
Drug: Rifampicin

First Posted Date: 2013-05-15

Last Posted Date: 2014-11-20

Lead Sponsor: Turku University Hospital

Target Recruit Count: 12

Registration Number: NCT01854489

Locations: 🇫🇮
Turku University Hospital, Turku, Finland

Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib

Phase 1

Completed

Conditions: Lymphoma
Solid Tumors

Interventions: Drug: Alisertib
Drug: Rifampin
Drug: Esomeprazole

First Posted Date: 2013-05-01

Last Posted Date: 2019-03-25

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 55

Registration Number: NCT01844583

A Drug Interaction Study of GDC-0032 Co-administered With Rifampin or Itraconazole in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: GDC-0032
Drug: Rifampin
Drug: Itraconazole

First Posted Date: 2013-03-20

Last Posted Date: 2016-11-02

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 32

Registration Number: NCT01814709

Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design

Phase 2

Completed

Conditions: Tuberculosis, Pulmonary

Interventions: Drug: SQ109
Drug: Rifampicin
Drug: Moxifloxacin
Drug: isoniazid
Drug: pyrazinamide
Drug: ethambutol
Dietary Supplement: pyridoxine

First Posted Date: 2013-02-07

Last Posted Date: 2017-09-20

Lead Sponsor: Michael Hoelscher

Target Recruit Count: 365

Registration Number: NCT01785186

Locations: 🇿🇦
The Aurum Institute for Health Research, Johannesburg, South Africa
🇿🇦
University of Cape Town, Centre for Tuberculosis Research Innovation, Cape Town, South Africa
🇹🇿
NIMR - Mbeya Medical Research Programme, Mbeya, Tanzania

and more 4 locations